Dignitana AB Publishes Q4 2022 Interim Report
Focused growth of 25 percent: Scaling up with a commitment to patients
Financial highlights Q4 2022
- Net sales amounted to 20.2 MSEK (16.2), an increase of 25 percent over the same period in 2021.
- Operating result amounted to -10.9 MSEK (-11.4).
- Net result after financial items amounted to -12.9 MSEK (-11.8).
- Earnings per share were -0.17 SEK (-0.10).
- Cash Balance amounted to 8.9 MSEK (14.5).
- Average Daily Treatment Revenue (ADTR)* was 229 TSEK (155), an increase of 48 percent over the same period in 2021.
Financial highlights January - December 2022
- Net sales amounted to 73.0 MSEK (57.1), an increase of 28 percent over the same period in 2021.
- Operating result amounted to -20.6 MSEK (-41.6).
- Net result after financial items amounted to -22.4MSEK (-43.1).
- Earnings per share were -0.34 SEK (-0.66).
Significant events during the period
- In October Dignitana announced a directed share issue of approximately 25 MSEK.
Business highlights during the period
- Dignitana appointed the Nomination Committee for the 2023 Annual General Meeting.
- Dignitana CEO Catarina Löwenadler was featured at the Aktiespararna Women’s Night in Stockholm. • In November Dignitana was featured at Stora Aktiedagen in Stockholm.
- Dignitana appointed Johan Johansson as VP Operations, Research and Development.
Business highlights after the period
- Dignitana’s prominent visibility in the breast cancer community continued with the Susan G. Komen® More Than Pink Walk in West Palm Beach, Florida.
Key Figures
| DIGNITANA GROUP | Q4 2022 | Q4 2021 | Full year 2021 | Full year 2021 |
| Net sales, TSEK | 20,245 | 16,213 | 72,995 | 57,073 |
| Total revenues, TSEK | 21,421 | 17,322 | 83,849 | 62,376 |
| Net profit after financial items, TSEK | -11,996 | -11,836 | -22,396 | -43,077 |
| Cash and bank balances, TSEK | 8,869 | 14,501 | 8,869 | 14,501 |
| Earnings per share before and after dilution, SEK | -0.17 | -0.18 | -0.34 | -0.66 |
| Average Daily Treatment revenue*, TSEK | 229 | 155 | 203 | 147 |
*ADTR includes pay-per-treatment revenue from patients and facilities in the U.S. Does not include lease revenue or disposable sales.
"Patient satisfaction fuels the passion of our team, keeping us laser-focused on continuing to grow Dignitana to its full potential." - Catarina Löwenadler, CEO Dignitana AB
All financial reports are available at www.dignitana.com/investor-relations/financial-reports/
This disclosure contains information that Dignitana AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 16-02-2023 08:00 CET.
